4 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 4 Phase 3, 2 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow meropenem and vaborbactam: new trials by email Literature Review of meropenem and vaborbactam trials Research Report on meropenem and vaborbactam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation Ceftazidime - Avibactam ( CAZ-AVI), Meropenem-Vaborbactam, Imipenem+Relebactam - Liver Transplant, Carbapenem-resistant Enterobacterales | Phase 3 | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 168 | 2026-10-01 | 2026-08-12 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis Meropenem-Vaborbactam, Antibiotics - Acute Pyelonephritis, Complicated Urinary Tract Infection | Phase 2 | Active not recruiting | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 66 | 2025-06-03 | 2026-09-10 |
| Optimising TREATment for Severe Gram-Negative Bacterial Infections Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem - Bloodstream Infection, Ventilator Associated Bacterial Pneumonia | Phase 4 | Recruiting | National University of Singapore | 600 | 2025-04-21 | 2025-06-04 |
| A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Meropenem-Vaborbactam, Piperacillin/Tazobactam - Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia | Phase 3 | Withdrawn | Melinta Therapeutics, Inc. | 2018-08-01 | 2019-01-11 | |
| Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers meropenem-vaborbactam, Placebo, Moxifloxacin - Healthy | Phase 1 | Completed | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | 53 | 2018-05-01 | 2019-01-10 |
| Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections Vabomere - Bacterial Infections | Phase 1 | Completed | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 39 | 2016-07-01 | 2026-08-17 |
| Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin - Urinary Tract Infection Complicated, Acute Pyelonephritis | Phase 3 | Completed | Melinta Therapeutics, Inc. | 550 | 2014-11-20 | 2018-06-11 |
| Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Vabomere, Best Available Therapy - Urinary Tract Infection Complicated, Acute Pyelonephritis | Phase 3 | Completed | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | 77 | 2014-07-01 | 2019-03-04 |
Bacteremia (1) · Bacterial Infections (1) · Healthcare-Associated Pneumonia (1) · Intraabdominal Infections (1) · Pneumonia, Ventilator-Associated (1) · Sepsis (1)
Melinta Therapeutics, Inc. (2) · Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) (2) · Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) (2) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · National University of Singapore (1)
United States (5) · Greece (3) · Italy (3) · Brazil (2) · Bulgaria (2) · Poland (2) · Spain (2) · Argentina (1) · Australia (1) · Belarus (1) · China (1) · Colombia (1) · Croatia (1) · Czechia (1) · Georgia (1)
Karen Fusaro (2) · Keith Kaye (2) · Maddalena Giannella, MD, PhD (1) · Sue Cammarata (1)
PMID 29486041, PMID 30270406, PMID 33565042, PMID 39964222
2016 (1), 2025 (1)